Novavax Inc Stock Price, News & Analysis

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company, will report its Q3 2020 financial and operational results on November 9, 2020, after U.S. market close. The conference call is scheduled for 4:30 p.m. ET on the same day. Interested parties can join via a domestic dial-in number (877) 212-6076 or international number (707) 287-9331, using passcode 8059421. The replay will be available from 7:30 p.m. ET on November 9 until November 16, 2020. Novavax is focused on developing vaccines for infectious diseases, including its COVID-19 vaccine candidate NVX-CoV2373.

Novavax, Inc. (Nasdaq: NVAX) has announced the expansion of its Gaithersburg campus, adding two properties to enhance its capabilities in vaccine research, manufacturing, and business operations. This move supports its ongoing COVID-19 vaccine trials and the development of its influenza vaccine, NanoFlu. The company has secured $2 billion in funding for its vaccine efforts, including $1.6 billion from the U.S. government. The new facilities will include 122,000 square feet for operations and will begin preparations for use in early 2021.

Novavax, Inc. (Nasdaq: NVAX) has enrolled over 5,500 participants in its U.K. Phase 3 clinical trial for NVX-CoV2373, aimed at assessing safety and efficacy against COVID-19. The trial will expand to 15,000 participants, with full enrollment expected by the end of November. Event-driven interim data may be available as early as Q1 2021. A U.S. Phase 3 trial is anticipated to start by the end of November, although it faced some manufacturing delays. Novavax will present new data from its ongoing Phase 1/2 trial during the CDC's ACIP meeting on October 30.

Novavax, Inc. (Nasdaq: NVAX) announced the presentation of its COVID-19 vaccine, NVX-CoV2373, at the virtual 2020 World Vaccine Congress Europe from October 19-21, 2020. Gregory M. Glenn, M.D., President of Research & Development, will discuss the recombinant nanoparticle vaccine platform. NVX-CoV2373 is engineered from the SARS-CoV-2 genetic sequence and incorporates Novavax's Matrix-M™ adjuvant to enhance immune response. The vaccine has shown promising results in preclinical trials and is in Phase 1 and Phase 3 clinical evaluations, supported by $2 billion in funding for its global vaccine program.

Novavax, Inc. (Nasdaq: NVAX) has formed a leadership team aimed at advancing its NanoFlu vaccine towards global licensure. Russell (Rip) Wilson has been promoted to Executive Vice President and NanoFlu General Manager, focusing on regulatory approvals for NanoFlu and a potential combined influenza/COVID-19 vaccine. The company intends to file a biologics licensing application (BLA) for NanoFlu, which has completed a successful Phase 3 trial. The new team includes experienced Novavax veterans to enhance development efforts across its vaccine pipeline.

Novavax (Nasdaq: NVAX) announced participation in four investor and industry conferences to discuss its COVID-19 vaccine candidate, NVX-CoV2373. Key events include the Maryland Life Sciences Bio Innovation Conference and the Guggenheim Vaccines and Infectious Diseases Conference, both on October 5, 2020. The vaccine uses proprietary recombinant nanoparticle technology and has shown promising results in clinical trials, demonstrating robust antibody responses. Novavax has secured $2 billion in funding for its global vaccine initiative, enhancing its position in addressing COVID-19.

Novavax, Inc. (Nasdaq: NVAX) announced its presentations at the 2020 World Vaccine Congress, featuring vaccines NVX-CoV2373, NanoFlu™, and ResVax™. Presenters Gregory Glenn and Vivek Shinde will discuss innovative vaccine development for COVID-19, influenza, and RSV from September 28 to October 1, 2020. Key presentation topics include the recombinant nanoparticle COVID-19 vaccine platform and new data on maternal RSV and influenza vaccines. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, emphasizing its commitment to addressing urgent public health needs.

Novavax, Inc. (Nasdaq: NVAX) announced its participation in the 2020 World Vaccine Congress, presenting updates on its vaccine candidates NVX-CoV2373 (COVID-19), NanoFlu™, and ResVax™. Key presentations include NVX-CoV2373's recombinant nanoparticle technology on September 28 and updates on maternal RSV and influenza vaccine programs on October 1. The company aims to address emerging infectious diseases and has secured significant funding, including $2 billion for its coronavirus vaccine initiatives. Experts from Novavax will collaborate with global leaders in public health during the congress.

On September 24, 2020, Maryland Governor Larry Hogan and BIO President Dr. Michelle McMurry-Heath highlighted Novavax's efforts in vaccine development against COVID-19 during an event at the company’s Gaithersburg facility. Novavax is preparing to initiate three Phase 3 trials for its vaccine candidate, NVX-CoV2373, with global trials in the UK, US, and India. The company's commitment reflects its responsibility to ensure widespread protection against the virus, underscoring the vital role of the biotechnology sector in combating health crises.